March 30, 2020 — Patients undergoing transcatheter aortic valve repair (TAVR) low-risk patients at two years did just as well compared with those undergoing open heart valve replacement surgery in...
Cath Lab
The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).
-
-
March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or...
-
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing transcatheter aortic valve replacement (TAVR) had a lower rate of bleeding complications...
-
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to patients following...
The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.
News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Edwards Lifesciences Corp. announced it is temporarily pausing new enrollments in its active...
Conclusions from the real world TAVR vs. surgery trial for aortic valve replacement outcomes in the U.K., presented by William D. Toff, M.D. at ACC 20.
News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR)...
Feature | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients undergoing transcatheter aortic valve repair (TAVR) low-risk patients at two years did...
News | Heart Valve Technology | March 29, 2020
March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing...
Feature | Heart Valve Technology | March 29, 2020 | Dave Fornell, Editor
March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve...
News | Atrial Fibrillation | March 29, 2020
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing...
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting.
News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to...
The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.
News | Peripheral Artery Disease (PAD) | March 28, 2020
March 28, 2020 — People with symptomatic...
News | Coronavirus (COVID-19) | March 27, 2020
March 27, 2020 — The European Society of Cardiology (ESC) has...
Videos | FFR Technologies | March 26, 2020
The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.
News | Heart Valve Technology | March 25, 2020
March 25, 2020 — CroiValve announced the successful first human use of its Duo Tricuspid Coaptation Valve...
Feature | Coronavirus (COVID-19) | March 20, 2020 | Dave Fornell, Editor
March 20, 2020 — The Centers for Medicare and Medicaid Services (CMS...
